Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Anqi Dai et al.|Nature Medicine|2022Cited by 308
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Joseph A. Fraietta et al.|Nature Medicine|2024Cited by 254
The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative DisorderMarlise R. Luskin, Ran Reshef, Daniel S. Heil et al.|American Journal of Transplantation|2015Cited by 174
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsSangya Agarwal, Carl H. June, M. Ángela Aznar et al.|Immunity|2023Cited by 164
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Bone Marrow Transplantation|2019Cited by 119